Treatments

Understand weight-management medicines

Indications, trials and follow-up to prepare a medical conversation.

Magnifying lens, prism and abstract shapes illustrating evidence reading. — AI-generated editorial illustration.

Start with the indication : Indication, Authorisation. Conceptual illustration; see the guide for explanations and sources.

Ozempic and weight loss: why its indication matters

Semaglutide has changed care for some people. To understand a proposed treatment, however, distinguish the active substance, brand, indication and results of the trial being cited.

Read the guide ↗

One substance, different indications : Type 2 diabetes, Weight management. Conceptual illustration; see the guide for explanations and sources.

Treatments

Ozempic or Wegovy: understanding the difference

The same active substance does not mean the same authorisation. A serious comparison starts with the medical reason for prescribing.

Read the guide ↗

STEP 1, 2021: 1,961 adults without diabetes, 68 weeks. Mean weight change: −14.9% with semaglutide 2.4 mg, −2.4% with placebo. Both groups received lifestyle support. An average does not predict an individual result.

Treatments

Semaglutide: reading the STEP 1 results

STEP 1 helps explain semaglutide’s efficacy within a defined setting. Its result is scientific evidence, not an individual forecast.

Read the guide ↗

Prepare a useful conversation : Objective, Medicines, Questions. Conceptual illustration; see the guide for explanations and sources.

Treatments

GLP-1: a checklist for your consultation

An appointment becomes more precise when you bring facts, everyday difficulties and a few written questions. This worksheet does not send health information anywhere.

Read the guide ↗

Compare the right studies : Tirzepatide, Semaglutide. Conceptual illustration; see the guide for explanations and sources.

Treatments

Mounjaro and semaglutide: comparing the right studies

Tirzepatide and semaglutide are different substances. A comparison must specify indications, populations and protocol.

Read the guide ↗

Product and support : Product, Clinical care. Conceptual illustration; see the guide for explanations and sources.

Treatments

“Strong” appetite suppressants: product or care pathway?

Advertised strength is not a care objective. Describe appetite difficulties through their effects and context first.

Read the guide ↗

The old review and the current status : Old review, Withdrawal, Check. Conceptual illustration; see the guide for explanations and sources.

Treatments

Sibutral and sibutramine: why an old review misleads

Sibutramine was subject to European suspension in 2010. A historical page listing it among ordinary weight-loss options omits an essential fact.

Read the guide ↗

Prepare to discuss tolerability : Record, Observe, Discuss. Conceptual illustration; see the guide for explanations and sources.

Treatments

GLP-1: preparing tolerability follow-up

Monitoring is more than weighing. Medicine information and prescriber instructions help distinguish routine questions from situations requiring medical contact.

Read the guide ↗

Consider follow-up after stopping : Anticipate, Discuss, Follow up. Conceptual illustration; see the guide for explanations and sources.

Treatments

After GLP-1 treatment: questions to anticipate

Discuss what follows treatment from the outset. A withdrawal study cannot predict your trajectory, but shows why follow-up extends beyond the last injection.

Read the guide ↗